NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
Saturday, November 16, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: Nurix's NX-5948, a clinical-stage BTK degrader, has shown significant promise by achieving deep suppression of BCR, TLR, and FcR signaling in immune cells. The compound demonstrated efficacy in preclinical models targeting arthritis and other inflammatory diseases, suggesting its potential as a breakthrough therapy in these areas.
Price reaction · baseline $22.92 (2024-11-15 close) · 2 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
-4.9%
Market Sentiment Analysis
POSITIVE FACTORS
NX-5948 shows deep suppression of BCR, TLR, and FcR signaling.
Demonstrated efficacy in preclinical models for arthritis.
Potential breakthrough therapy for inflammatory diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is NX-5948?
NX-5948 is a clinical-stage BTK degrader developed by Nurix.
What diseases does NX-5948 target?
NX-5948 targets arthritis and other inflammatory diseases.
How does NX-5948 work?
It achieves deep suppression of BCR, TLR, and FcR signaling in immune cells.
What were the results in preclinical models?
NX-5948 demonstrated efficacy in preclinical models for arthritis.